Wedbush Issues Positive Outlook for Arvinas Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at Wedbush upped their Q1 2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.76) per share for the quarter, up from their prior estimate of ($0.93). Wedbush currently has a “Neutral” rating and a $12.00 target price on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the business posted ($2.53) earnings per share.

ARVN has been the subject of a number of other reports. BMO Capital Markets set a $20.00 price target on Arvinas and gave the company an “outperform” rating in a report on Wednesday, March 12th. Guggenheim lowered their price objective on Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. BTIG Research began coverage on Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. Barclays lowered their price objective on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, Oppenheimer downgraded Arvinas from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 11th. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.47.

Arvinas Trading Up 3.2 %

Shares of NASDAQ ARVN opened at $8.70 on Monday. Arvinas has a twelve month low of $7.91 and a twelve month high of $45.03. The company has a market capitalization of $598.32 million, a price-to-earnings ratio of -3.14 and a beta of 1.95. The business has a 50 day simple moving average of $17.09 and a 200-day simple moving average of $21.71.

Insiders Place Their Bets

In other news, CEO John G. Houston sold 31,338 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares in the company, valued at $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by company insiders.

Institutional Trading of Arvinas

Several institutional investors have recently modified their holdings of ARVN. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Arvinas in the fourth quarter valued at $42,332,000. Norges Bank purchased a new stake in shares of Arvinas during the fourth quarter valued at $23,845,000. Boxer Capital Management LLC purchased a new stake in shares of Arvinas during the fourth quarter valued at $20,294,000. Braidwell LP lifted its holdings in shares of Arvinas by 148.3% during the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after purchasing an additional 767,242 shares during the last quarter. Finally, RTW Investments LP lifted its holdings in shares of Arvinas by 19.8% during the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock valued at $63,919,000 after purchasing an additional 551,979 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.